HOME > BUSINESS
BUSINESS
- Asklep to Establish Joint Venture Company with US CRO ReSearch Pharmaceutical Services
April 1, 2013
- GSK's Operating Profit Down 22% in 2012 due to Cervarix Sales Drop
March 29, 2013
- Takeda Files NDA for Fixed-Dose Combination of Takepron, Low-Dose Aspirin in Japan
March 29, 2013
- Takeda Files NDAs for Cell Culture-Based New Flu Vaccines
March 29, 2013
- Shionogi Settles Crestor Lawsuit in US
March 28, 2013
- Equa Tops February Detailing Ranking in GP, HP Markets, Driven by Expanded Concurrent Use: Rep Track Survey
March 28, 2013
- First Time NDA Filed in Japan for Meningococcal Vaccine: Sanofi
March 28, 2013
- Otsuka, Lundbeck to Jointly Develop, Market Alzheimer’s Disease Drug
March 28, 2013
- AnGes Licenses Nucleic Acid Drug for Diseases Causing Lower Back Pain to Nippon Zoki in Japan
March 28, 2013
- Takeda, Novartis Rank 1st in Total Average Score with Favorable Impression on Quality of Development: IAL Survey
March 28, 2013
- Concurrent-Use Indications Approved for Trazenta: NBI, Eli Lilly Japan
March 27, 2013
- ASKA Targets Sales of 50 Billion yen in FY2015, Up 20% vs. FY2012 Outlook: 3-Year Plan
March 27, 2013
- New Parkinson’s Disease Treatment Nouriast Approved: Kyowa Kirin
March 27, 2013
- FD Treatment Acofide Approved: Zeria, Astellas
March 27, 2013
- Otsuka Receives Approval for DPP-4 Inhibitor Onglyza, to Transfer Marketing Rights to Kyowa Kirin
March 27, 2013
- Takeda Announces Full Cancellation of Correction Notice Based on Transfer Pricing Tax System; 15.2 Billion Yen Refund Expected
March 27, 2013
- Marc Dunoyer Steps Down as Chairman of GSK K.K.
March 26, 2013
- Terumo Launches Cancer Pain Treatment Methapain
March 26, 2013
- Takeda Files NDA for Malignant Lymphoma Treatment Brentuximab Vedotin in Japan
March 26, 2013
- JAK Inhibitor Xeljanz Approved for RA: Pfizer Japan
March 26, 2013
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…